Novo Nordisk Stock Jumps 6%: Wegovy Pill Beats Forecasts

Novo Nordisk shares jumped about 6% in Copenhagen on Wednesday, November 4, 2026, after the Danish drugmaker beat third-quarter forecasts, its Wegovy weight-loss pill topped sales expectations, and the company raised its full-year outlook. The stock rose to DKK 286.70 from a previous close of DKK 270.15 in early trading, as investors got the clearest sign yet that Novo's oral obesity drug can help it fight back against rival Eli Lilly.

What happened?

Novo Nordisk reported third-quarter adjusted sales of DKK 79.20 billion, well above the DKK 73.22 billion analysts had expected in company-compiled consensus, according to Reuters. Adjusted operating profit came in at DKK 31.72 billion, ahead of the DKK 28.39 billion projected and up 27% at constant exchange rates from a year earlier. Sales grew 4% at constant exchange rates, driven by continued GLP-1 volume growth in the US and international operations, primarily in obesity, the company said in its financial report for the first nine months of 2026.

The standout was the Wegovy pill. Sales of the pill, launched in the United States in January, reached DKK 5.39 billion (about $810 million) in the quarter, up 53% from the second quarter and above the DKK 4.62 billion forecast. By the end of the quarter the pill had been launched in the US, UAE, UK and Germany, and launches in four more countries have since taken the total to eight markets. The Wegovy franchise also kept its US leadership in new patient starts, with more than 50% share of the branded obesity market.

Key facts

• Share move: Novo Nordisk B shares rose about 6.1% to DKK 286.70 in Copenhagen, from a previous close of DKK 270.15.
• Sales: Q3 adjusted sales of DKK 79.195 billion, up 6% in Danish kroner and 4% at constant exchange rates, beating the roughly DKK 73.2-73.6 billion consensus.
• Profit: Adjusted operating profit of DKK 31.72 billion, up 27% at constant exchange rates, beating the DKK 28.39 billion forecast.
• Wegovy pill: Sales of DKK 5.394 billion, up 53% quarter on quarter and above the DKK 4.62 billion forecast.
• Outlook raised: Full-year 2026 adjusted sales and adjusted operating profit growth are now expected at -2% to +2% at constant exchange rates, up from a previous forecast of a 0% to 6% fall.
• The catch: Reported operating profit fell 9% at constant exchange rates, reflecting DKK 8.7 billion of non-cash impairment charges, and reported net profit fell 16% year on year to DKK 16.74 billion.

Why is it blowing up?

This quarter was a test. Novo, once Europe's most valuable listed company on booming Wegovy sales, has endured a two-year slump of profit warnings and a leadership change while Eli Lilly's rival treatments won ground, including Lilly's Foundayo pill. Analysts see the Wegovy pill as Novo's main route back to growth, even though it still makes up only a small share of total sales. A 53% jump in pill sales in a single quarter, plus a guidance raise instead of another cut, is exactly the evidence investors had been waiting for.

The raised outlook matters for the same reason. Novo now expects adjusted sales and profit for 2026 to land between a 2% fall and 2% growth at constant exchange rates, driven by increased expectations for GLP-1 product sales. CEO Mike Doustdar said the company delivered a stronger-than-expected quarter, with growth led by the obesity portfolio and continued uptake of the Wegovy pill in the US alongside encouraging early launches internationally.

What is next?

The focus now shifts to execution. Novo is rolling out higher-dose Ozempic and Wegovy pens internationally, and is preparing for a possible US launch of its next obesity candidate, CagriSema, in early 2027, subject to regulatory approval. Investors will watch whether pill sales keep compounding and whether Novo can hold its lead in new patient starts against Lilly.

Sources

• Reuters — Novo Nordisk's Wegovy pill beats forecasts as it battles Lilly
• Novo Nordisk company announcement (GlobeNewswire) — Q3 2026 financial report
• Sweden Herald — Novo Nordisk beats third-quarter expectations as Wegovy sales rise
• Seeking Alpha — Novo Nordisk beats top-line and bottom-line estimates; updates FY26 outlook

FAQ

Why did Novo Nordisk stock jump on November 4, 2026?

Shares rose about 6% in Copenhagen after third-quarter sales and adjusted operating profit beat analyst forecasts, Wegovy pill sales topped expectations, and the company raised its full-year outlook.

How much did the Wegovy pill sell in Q3 2026?

The Wegovy pill sold DKK 5.39 billion (about $810 million) in the quarter, up 53% from the second quarter and above the DKK 4.62 billion forecast.

What is Novo Nordisk's new outlook for 2026?

Novo now expects adjusted sales growth and adjusted operating profit growth of -2% to +2% at constant exchange rates for 2026, raised from a previous forecast of a 0% to 6% fall.

Why did reported profit fall if the quarter beat forecasts?

Reported operating profit fell 9% at constant exchange rates because of DKK 8.7 billion in non-cash impairment charges linked to ziltivekimab and right-sizing the manufacturing network; the adjusted figures exclude those charges.

This article reports market news only and is not financial advice.